Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials

BACKGROUND: Symptoms of advanced hepatocellular carcinoma (HCC) represent a substantial burden for the patient and are important endpoints to assess when evaluating treatment. Patient-reported outcomes were evaluated in subjects with advanced HCC and baseline alpha-fetoprotein (AFP) ≥400 ng/mL treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Andrew X, Nipp, Ryan D, Finn, Richard S, Galle, Peter R, Llovet, Josep M, Blanc, Jean-Frederic, Okusaka, Takuji, Chau, Ian, Cella, David, Girvan, Allicia, Gable, Jonathon, Bowman, Lee, Wang, Chunxiao, Hsu, Yanzhi, Abada, Paolo B, Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437873/
https://www.ncbi.nlm.nih.gov/pubmed/32817068
http://dx.doi.org/10.1136/esmoopen-2020-000797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437873/
https://www.ncbi.nlm.nih.gov/pubmed/32817068
http://dx.doi.org/10.1136/esmoopen-2020-000797

Ejemplares similares